A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice.
OBJECTIVE: The role of fibroblast growth factors (FGFs) in the development of vascular diseases remains incompletely understood. The objective of this study was to examine the effects of a new small-molecule multi-FGF receptor blocker with allosteric properties, SSR128129E, on neointimal proliferati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3817113?pdf=render |
| _version_ | 1819124605604855808 |
|---|---|
| author | Frédérique Dol-Gleizes Nathalie Delesque-Touchard Anne-Marie Marès Anne-Laure Nestor Paul Schaeffer Françoise Bono |
| author_facet | Frédérique Dol-Gleizes Nathalie Delesque-Touchard Anne-Marie Marès Anne-Laure Nestor Paul Schaeffer Françoise Bono |
| author_sort | Frédérique Dol-Gleizes |
| collection | DOAJ |
| description | OBJECTIVE: The role of fibroblast growth factors (FGFs) in the development of vascular diseases remains incompletely understood. The objective of this study was to examine the effects of a new small-molecule multi-FGF receptor blocker with allosteric properties, SSR128129E, on neointimal proliferation after a vein graft procedure in mice and on the development of atherosclerosis in atherosclerosis-prone apolipoprotein E (apoE)-deficient mice. METHODS AND RESULTS: Vein grafts were performed in 3 month-old male C57BL6 mice. Segments of the vena cava were interposed at the level of the carotid artery. In SSR128129E (50 mg/kg/d)-treated animals, a dramatic decrease in neointimal proliferation was observed 2 and 8 weeks after the graft (72.5%, p<0.01, and 47.8%, p<0.05, respectively). Four-week old male apoE-deficient mice were treated with SSR128129E (50 mg/kg/d) for 3 and 5 months in comparison with a control group. SSR128129E treatment resulted in a reduction of lesion size in the aortic sinus (16.4% (ns) at 3 months and 42.9% (p<0.01) at 5 months, without any change in serum lipids. SSR128129 significantly reduced FGFR2 mRNA levels in the aortic sinus (p<0.05, n=5-6), but did not affect the mRNA expression levels of other FGF receptors or ligands. CONCLUSION: These studies indicate that FGFs have an important role in the development of vascular diseases like atherosclerosis and graft arteriosclerosis. These data suggest that inhibition of FGF receptors by compounds like SSR128129E might be useful as a new therapeutic approach for these vascular pathologies. |
| first_indexed | 2024-12-22T07:26:54Z |
| format | Article |
| id | doaj.art-56fe1f89cc5b4ff699b940eb16bd7da3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T07:26:54Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-56fe1f89cc5b4ff699b940eb16bd7da32022-12-21T18:34:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e8002710.1371/journal.pone.0080027A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice.Frédérique Dol-GleizesNathalie Delesque-TouchardAnne-Marie MarèsAnne-Laure NestorPaul SchaefferFrançoise BonoOBJECTIVE: The role of fibroblast growth factors (FGFs) in the development of vascular diseases remains incompletely understood. The objective of this study was to examine the effects of a new small-molecule multi-FGF receptor blocker with allosteric properties, SSR128129E, on neointimal proliferation after a vein graft procedure in mice and on the development of atherosclerosis in atherosclerosis-prone apolipoprotein E (apoE)-deficient mice. METHODS AND RESULTS: Vein grafts were performed in 3 month-old male C57BL6 mice. Segments of the vena cava were interposed at the level of the carotid artery. In SSR128129E (50 mg/kg/d)-treated animals, a dramatic decrease in neointimal proliferation was observed 2 and 8 weeks after the graft (72.5%, p<0.01, and 47.8%, p<0.05, respectively). Four-week old male apoE-deficient mice were treated with SSR128129E (50 mg/kg/d) for 3 and 5 months in comparison with a control group. SSR128129E treatment resulted in a reduction of lesion size in the aortic sinus (16.4% (ns) at 3 months and 42.9% (p<0.01) at 5 months, without any change in serum lipids. SSR128129 significantly reduced FGFR2 mRNA levels in the aortic sinus (p<0.05, n=5-6), but did not affect the mRNA expression levels of other FGF receptors or ligands. CONCLUSION: These studies indicate that FGFs have an important role in the development of vascular diseases like atherosclerosis and graft arteriosclerosis. These data suggest that inhibition of FGF receptors by compounds like SSR128129E might be useful as a new therapeutic approach for these vascular pathologies.http://europepmc.org/articles/PMC3817113?pdf=render |
| spellingShingle | Frédérique Dol-Gleizes Nathalie Delesque-Touchard Anne-Marie Marès Anne-Laure Nestor Paul Schaeffer Françoise Bono A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE |
| title | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. |
| title_full | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. |
| title_fullStr | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. |
| title_full_unstemmed | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. |
| title_short | A new synthetic FGF receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein E-deficient mice. |
| title_sort | new synthetic fgf receptor antagonist inhibits arteriosclerosis in a mouse vein graft model and atherosclerosis in apolipoprotein e deficient mice |
| url | http://europepmc.org/articles/PMC3817113?pdf=render |
| work_keys_str_mv | AT frederiquedolgleizes anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT nathaliedelesquetouchard anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT annemariemares anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT annelaurenestor anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT paulschaeffer anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT francoisebono anewsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT frederiquedolgleizes newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT nathaliedelesquetouchard newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT annemariemares newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT annelaurenestor newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT paulschaeffer newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice AT francoisebono newsyntheticfgfreceptorantagonistinhibitsarteriosclerosisinamouseveingraftmodelandatherosclerosisinapolipoproteinedeficientmice |